Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. [electronic resource]
Producer: 20210707Description: 307-319 p. digitalISSN:- 1600-0641
- Angiogenesis Inhibitors -- therapeutic use
- Antibodies, Monoclonal, Humanized -- therapeutic use
- Antineoplastic Agents, Immunological -- therapeutic use
- B7-H1 Antigen -- antagonists & inhibitors
- Biomarkers, Tumor -- blood
- CTLA-4 Antigen -- antagonists & inhibitors
- Carcinoma, Hepatocellular -- blood
- Combined Modality Therapy -- methods
- Humans
- Immune Checkpoint Inhibitors -- pharmacology
- Immunotherapy -- methods
- Liver Neoplasms -- blood
- Programmed Cell Death 1 Receptor -- antagonists & inhibitors
- Progression-Free Survival
- T-Lymphocytes -- immunology
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.